Mira Pharmaceuticals Inc (NASDAQ: MIRA) has experienced a decline in its stock price by -15.50 compared to its previous closing price of 2.71. However, the company has seen a fall of -54.29% in its stock price over the last five trading days. accesswire.com reported 2024-07-25 that Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine analog MIAMI, FL / ACCESSWIRE / July 25, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a leading pre-clinical-stage pharmaceutical company, today announced new insights garnered from additional, recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2. Ketamir-2 is MIRA’s drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders.
Is It Worth Investing in Mira Pharmaceuticals Inc (NASDAQ: MIRA) Right Now?
There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MIRA is 9.75M, and at present, short sellers hold a 0.17% of that float. The average trading volume of MIRA on July 30, 2024 was 4.65M shares.
MIRA’s Market Performance
The stock of Mira Pharmaceuticals Inc (MIRA) has seen a -54.29% decrease in the past week, with a 252.31% rise in the past month, and a 166.34% gain in the past quarter. The volatility ratio for the week is 46.28%, and the volatility levels for the past 30 days are at 35.84% for MIRA. The simple moving average for the past 20 days is 80.16% for MIRA’s stock, with a 66.56% simple moving average for the past 200 days.
MIRA Trading at 135.26% from the 50-Day Moving Average
After a stumble in the market that brought MIRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.30% of loss for the given period.
Volatility was left at 35.84%, however, over the last 30 days, the volatility rate increased by 46.28%, as shares surge +259.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +225.15% upper at present.
During the last 5 trading sessions, MIRA fell by -54.29%, which changed the moving average for the period of 200-days by -40.36% in comparison to the 20-day moving average, which settled at $1.35. In addition, Mira Pharmaceuticals Inc saw 118.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRA starting from Aminov Erez, who purchase 8,700 shares at the price of $0.94 back on May 21 ’24. After this action, Aminov Erez now owns 382,200 shares of Mira Pharmaceuticals Inc, valued at $8,176 using the latest closing price.
McNulty Brian Patrick, the 10% Owner of Mira Pharmaceuticals Inc, sale 46,005 shares at $1.55 during a trade that took place back on Dec 11 ’23, which means that McNulty Brian Patrick is holding 660,000 shares at $71,496 based on the most recent closing price.
Stock Fundamentals for MIRA
The total capital return value is set at -2.84. Equity return is now at value -1807.80, with -587.64 for asset returns.
Based on Mira Pharmaceuticals Inc (MIRA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -4404.34. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -2.55.
Currently, EBITDA for the company is -8.53 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.70.
Conclusion
In summary, Mira Pharmaceuticals Inc (MIRA) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
